Anti-neutrophil cytoplasmic autoantibodies directed toward myeloperoxidase or proteinase 3 are detected in sera of patients with small vessel vasculitis and participate in the pathogenesis of this disease. Autoantibodies develop when self-reactive B cells escape the regulation that ensures self-tolerance. In this study, regulation of anti-myeloperoxidase B cells was examined in mice that express an antimyeloperoxidase V1C-J5 light-chain transgene, which confers anti-myeloperoxidase specificity when combined with a variety of heavy chains. V1C-J5 transgenic mice have splenic anti-myeloperoxidase B cells but do not produce circulating anti-myeloperoxidase antibodies. Two groups of transgenic mice that differed by their relative dosage of the transgene were compared; high-copy mice had a mean relative transgene dosage of 1.92 compared with 1.02 in the low-copy mice. These mice exhibited a 90 and 60% decrease in mature follicular B cells, respectively. High-copy mice were characterized by a large population of anti-myeloperoxidase B cells, a preponderance of B-1 cells, and an increased percentage of apoptotic myeloperoxidase-binding B cells. Low-copy mice had similar changes in B cell phenotype with the exception of an expanded marginal zone population. B cells from low-copy mice but not high-copy mice produced anti-myeloperoxidase antibodies after stimulation with lipopolysaccharide. These results indicate that tolerance to myeloperoxidase is maintained by central and peripheral deletion and that some myeloperoxidase-binding B cells are positively selected into the marginal zone and B-1 B cell subsets. A defect in these regulatory pathways could result in autoimmune disease.
Anti-neutrophil cytoplasmic autoantibodies (ANCA), directed against myeloperoxidase (MPO) and proteinase 3 (PR3), are detected in 90% of patients with small vessel vasculitis, including Wegener's granulomatosis, microscopic polyangiitis, and pauci-immune necrotizing crescentic glomerulonephritis. 1, 2 Many in vitro 2, 3 and in vivo studies 4 -8 demonstrated that ANCA participate in the pathogenesis of small vessel vasculitis. Less work has focused on understanding the immunopathogenesis of the ANCA autoimmune response. Previous studies suggested that the human MPO-ANCA response is highly restricted. 9 To investigate this response further, we used an anti-MPO antibody derived from SCG/Kj mice, a recombinant inbred strain that spontaneously develops vasculitis and crescentic glomerulonephritis.
Although SCG/Kj mice may not be a good model for pauci-immune glomerulonephritis, 30% of these mice spontaneously develop anti-MPO anti-bodies. 10, 11 These anti-MPO antibodies are useful in studying the derivation of this autoimmune response. Previously, we demonstrated a restriction in V gene use in anti-MPO-producing hybridomas derived from SCG/Kj mice. 12 This restriction suggests an important role of the Ig light chain in determining specificity to MPO.
The aims of this study were to determine the role of the Ig light chain in determining specificity of anti-MPO antibodies and the mechanism of anti-MPO B cell regulation in a nonautoimmune animal model. Using mice transgenic (Tg) for the V1C-J5 light chain derived from an anti-MPO hybridoma from SCG/Kj mice, we investigated several questions. Does expression of the V1C-J5 light chain lead to the generation of anti-MPO B cells? Do anti-MPO B cells produce circulating anti-MPO antibodies? If not, then at which point in their maturation are the B cells regulated to maintain a state of immune tolerance to MPO? The answers to these questions will contribute to our understanding of how tolerance is maintained in normal individuals and how a breakdown in these mechanisms can lead to the generation of anti-MPO antibodies and autoimmune disease.
RESULTS

V1C-J5 Light-Chain Tg Mice
To study the regulation of anti-MPO B cells, we generated mice transgenic for the rearranged V1C-J5 gene derived from an anti-MPO hybridoma ( Figure 1A ). 12 Interbreeding produced two groups of V1C-J5 Tg mice that differed in their relative number of copies of the transgene ( Figure 1B) . Mice with the larger number of transgene copies are referred to as "high copy" (HC) mice and the other group as "low copy" (LC) mice. Quantitative PCR analysis revealed that HC Tg mice had a mean 2 (ϪDDct) of 1.92 Ϯ 0.7 of measured transgene in their genomic DNA compared with the LC Tg mice mean 2 (ϪDDct) of 1.02 Ϯ 0.2 (P ϭ 0.0018).
Tg Mice Have MPO-Binding B Cells but no Circulating Anti-MPO Antibodies
To test whether the V1C-J5 light-chain transgene was sufficient to produce anti-MPO B cells, we searched for MPObinding cells by FACS analysis. Splenocytes of LC (3.0 Ϯ 0.7%) and HC mice (9.7 Ϯ 8.1%) had a significantly increased percentage of MPO-binding B cells when compared with control mice (1.5 Ϯ 0.6%; P Ͻ 0.0001; Figure 1 , C and 1D). Likewise, the percentage of MPO-binding B cells in the bone marrow of LC and HC mice (6.3 Ϯ 2.3 and 13.7 Ϯ 4.8%, respectively) was significantly greater than in controls (2.1 Ϯ 0.9%; P Ͻ 0.0001; Table 1 ). In contrast, no PR3-binding B cells could be detected in Tg mice, indicating that binding of MPO is specific. Despite the documented presence of anti-MPO B cells, no Tg mice were found to have circulating anti-MPO antibodies as determined by ELISA against either native human MPO or recombinant mouse MPO when compared with non-Tg mice.
V1C-J5 Splenocytes Can Produce Anti-MPO Antibodies
To verify that the Tg V1C/J5 light chain participates in the production of secreted anti-MPO antibodies, we gener- To verify expression of the V1C/J5 light-chain transgene and determine whether the Tg light chain conferred allelic exclusion, we analyzed seven anti-MPO hybridomas by 5Ј RACE using primers in the C region. Sequencing revealed that the light-chain transgene alone was expressed in four of seven hybridomas examined (Table 2) . Two hybridomas expressed V12-41 in addition to the V1C Tg, and one hybridoma expressed V21-4 alone ( Table 2 ), indicating that the transgene 
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had not conferred allelic exclusion in all cells. We also determined that four different heavy chains paired with the V1C/J5 light-chain transgene to create anti-MPO antibodies (Table 2 ) in addition to the V H 3609 heavy chain expressed by the original anti-MPO hybridoma ( Table 2) . These results demonstrate that the V1C/J5 light chain can confer anti-MPO specificity when combined with a variety of heavy chains.
For determination of whether anti-MPO splenocytes were anergic, total splenocytes and B cells were cultured in the presence or absence of MPO, LPS, or anti-IgM. Anti-MPO antibodies were produced in splenocytes and B cells from LC Tg but not HC Tg stimulated with LPS (Supplemental Figure 1 To investigate why expression of the V1C/J5 light chain produced anti-MPO B cells but not circulating anti-MPO antibodies, we looked for alterations in B cell differentiation. In the bone marrow, the percentage of B220 ϩ B cells was markedly reduced in both LC (11.8 Ϯ 3.5%) and HC Tg mice (7.8 Ϯ 8.7%) compared with control mice (50.2 Ϯ 19.8%; P ϭ 0.0002; Table 1 ), corresponding to a decrease in the total number of B220 ϩ B cells of 85 and 93%, respectively. To determine whether B cell development was altered in the bone marrow, pro-/pre-B cells, immature B cells, and recirculating mature B cells were distinguished by staining with B220 and IgM. The number of IgM ϩ /B220
hi recirculating B cells was reduced by 70% in LC mice and 95% in HC mice (Table 1) . Similarly, the number of pro-/pre-B cells was decreased by 90% in HC mice and by 60% in LC mice. The number of IgM ϩ /B220
ϩ immature B cells was reduced by 66% in LC mice and 79% in HC mice ( Table 1 ). The ratio of pro-/pre-B cells to immature B cells is not higher in LC or HC Tg (4.6:1 and 2.6:1, respectively) compared with control mice (6.4:1), suggesting that there is no block in development of pro-/pre-B cells to immature B cells in Tg mice.
In the spleen, the percentage of total IgM ϩ and/or B220 ϩ splenic B cells was decreased significantly in both LC (48.1 Ϯ 9.9%) and HC (22.4 Ϯ 17.9%) Tg mice compared with control mice (65.6 Ϯ 7.1%; P Յ 0.0001). Similarly, the absolute number of splenic B cells is reduced by 30% in LC mice and 60% in HC mice. In the peritoneal cavity, we found no significant differences in the absolute number or the percentage of IgM ϩ B cells in Tg as compared with control mice (Table 1) .
Tg Mice Exhibit a Decrease in Mature Follicular Cells
Tg mice demonstrated altered splenic B cell subpopulations when compared with non-Tg mice. Antibodies to CD23, CD21, and IgM were used to distinguish mature follicular
Ϫ could be either B-1 or transitional 1 (T1) B cells and are referred to as T1/B1 cells. 13 Representative CD21/CD23 histograms are presented in Figure 2 . LC mice had increased percentages of marginal zone and T1/B-1 cells and a decreased percentage of mature follicular cells ( Figure 2C ). In HC mice, the majority of B cells were T1/B-1 with few marginal zone or follicular cells ( Figure 2D ). Differences among the three groups are summarized in Figure 2E . Compared with controls (73.6 Ϯ 7.7%), LC mice had a 70% (23.1 Ϯ 9.0%; P Ͻ 0.0001) and HC mice a 93% (5.2 Ϯ 4.4%; P Ͻ 0.0001) decrease in the percentage of mature splenic follicular cells. LC mice had an increased percentage of marginal zone (39.5 Ϯ 10.2%; P Ͻ 0.0001; confirmed by staining with an antibody to the marginal zone-specific marker CD9) and T1/B-1 B cells (31.5 Ϯ 13.4%; P Ͻ 0.0001). HC mice had a preponderance of T1/B-1 B cells (79.1 Ϯ 16.7%) greater than that found in either LC or control mice (P Ͻ 0.0001); however, the percentage of marginal zone cells was no different from controls. When absolute cell numbers were considered, these alterations in splenic follicular and marginal zone B cell subpopulations were confirmed (Table 1) .
To control mice (7.5 Ϯ 4.3%; P Ͻ 0.0001; Figure 3 , A, B, and E). Although we noted a trend toward increased numbers of B-1 cells in LC and HC mice, the absolute number of B-1 cells did not differ significantly. We observed no statistically significant differences in either the number or the percentage of B-1 cells in the peritoneal cavity of Tg mice compared with control mice (Table 1) .
MPO-Binding Cells Are Marginal Zone and B-1 B Cells
We observed a significant percentage of MPO-binding B cells in spleens of Tg mice. Although MPO-binding splenic B cells are rare in non-Tg control mice, half of these MPO binders have a follicular cell phenotype (Table 1) , whereas the percentage of MPO binders that progress to the follicular stage is reduced in both LC and HC Tg mice 
DISCUSSION
The purpose of this work was to elucidate the regulation of the anti-MPO response in nonautoimmune mice and to assess the ability of the antibody light chain to confer specificity to MPO. To this end, we used a V1C-J5 anti-MPO light chain derived from an anti-MPO hybridoma generated from SCG/Kj mice 10 to produce Tg mice. We identified two groups of Tg mice that exhibit altered B cell phenotypes compared with non-Tg controls. The phenotypic differences in LC and HC mice correlated with a doubling of the relative transgene copy number in the HC mice. It is possible that the observed differences in phenotype could result from a "transgene effect" that alters another gene as a result of the site of insertion; however, we believe that this is unlikely. The B cell phenotype of mice from three additional founder lines also correlated with relative transgene copy number (data not shown). We detected anti-MPO B cells in both groups of Tg mice; however, none expressed circulating anti-MPO antibody. These results indicate that anti-MPO B cells are regulated to prevent anti-MPO antibody production and maintain tolerance in this mouse model. Much work has demonstrated that tolerance to self-antigens may be achieved by anergy, clonal deletion, or receptor editing of autoreactive B cells. 14 -22 An important question is whether anti-MPO B cells are functional. Generation of anti-MPO hybridomas from LC Tg mice confirmed the presence of anti-MPO B cells and demonstrated that the V1C-J5 Tg can confer anti-MPO specificity when combined with a variety of rearranged heavy chains. Although several of the heavy chains from V1C-J5 Tg hybridomas expressed the J558 variable region gene, the number of hybridomas examined was too small to ascertain whether there is a restriction in heavy-chain variable region gene use by anti-MPO B cells. Of note, one of the non-Tg light chains, V12-41, expressed by hybridomas from our V1C-J5 Tg mice, is also expressed by another anti-MPO antibody produced by NZB ϫ NZW mice, 23 We examined the B cell repertoire to elucidate further the mechanisms of maintaining tolerance to MPO in this nonautoimmune mouse model. We observed Ͼ85% fewer B cells in the bone marrow of Tg mice, in part because of reduced clonal expansion at the pre-B cell stage as a result of expression of the light-chain transgene. Our data also support the deletion of anti-MPO B cells in the bone marrow. These results are similar to those found with anti-red blood cell (RBC) 24 and anti-DNA Tg mice. 18 Moreover, we observed a large population of apoptotic MPO-binding B cells in the spleens of Tg mice, suggesting that deletion of anti-MPO B cells continues in the periphery, most likely via the extrinsic pathway of apoptosis because caspase 8 is activated. 25 Peripheral deletion of self-reactive B cells by apoptosis has been demonstrated in other Tg mouse models, including MTb Tg ϫ 3-83 ␦ Tg mice 26 and anti-RBC Tg mice. 27 In Tg mice, we observed almost complete elimination of mature recirculating B cells in the bone marrow and follicular cells in the spleen. This decreased progression of B cells to the follicular stage was accompanied by diversion of B cells to either a marginal zone or B-1 phenotype. These changes affect MPO-binding cells as well as cells that seem to be non-MPObinding cells. A likely explanation is that there are more MPObinding B cells present than we detect by FLOW cytometry using biotinylated MPO. B cells classified as "non-MPO-binding B cells" may actually include MPO binders with an affinity or avidity for MPO that is too low to sustain strong binding of the biotinylated MPO molecule. LC mice are characterized by a four-fold increase in the number of marginal zone B cells. This finding is consistent with considerable evidence that autoreactive B cells are selected into the marginal zone of the spleen. 28 -30 Marginal zone B cells may arise from autoreactive cells through the process of receptor editing, which can result in the expression of two receptors and effectively dilute the autoreactive B cell receptor signal strength. 28 Such receptor editing may occur in LC Tg mice as evidenced by the fact that two anti-MPO-binding hybridomas also expressed a different light chain in addition to the Tg Vk1C-Jk5. We hypothesize that receptor editing, with a resultant lack of allelic exclusion and production of marginal zone B cells, may be one of the mechanisms used by LC Tg mice to negatively regulate autoreactive cells.
In contrast to LC mice, HC mice did not exhibit an increase in marginal zone cells but rather a marked increase in B-1 cells in the spleen. This diversion of autoreactive B cells into the B-1 compartment has been observed in other Tg mouse models. 31, 32 B-1 cells express high levels of CD5, a molecule known to regulate negatively B cell receptor signaling and, therefore, reduce antibody production. 33 B cell antigen receptor specificity and surface density have been shown to drive B-1 versus follicular cell development. 34, 35 Although we detected an increase in splenic B-1 cells, not peritoneal B-1 cells, our results are comparable to those of the tandem anti-RBC heavy-and light-chain Tg mouse, 35 in which homozygosity of the transgene resulted in deletion of follicular cells from both bone marrow and spleen and an increase in peritoneal B-1 cells. Our results parallel this Tg model whereby the relative copy number drove the B cell phenotype. We see an increase in marginal zone cells in our V1C-J5 Tg mice that have fewer copies of the transgene and a diversion of B cells to the B-1 subtype in mice with the larger relative transgene copy number. Gene copy number correlates with expression levels of the corresponding protein, 30, [35] [36] [37] [38] [39] and B cell receptor density is known to affect B cell receptor signal strength. 28, 34 Our results are consistent with the B cell receptor signal strength model, which proposes that B cell receptor signaling determines peripheral B cell lineage commitment. 40, 41 Specifically, a weak B cell receptor signal drives production of marginal zone B cells, and a strong B cell receptor signal triggers B-1 B cell production.
In conclusion, our results are consistent with a model of autoreactive B cell regulation whereby anti-MPO B cells are deleted via apoptosis in the bone marrow and in the spleen before maturation to follicular B cells. Anti-MPO B cells that survive this negative selection are diverted to a B-1 phenotype or to a marginal zone phenotype depending on B cell receptor strength, apparently determined by the relative transgene copy number. Moreover, remaining anti-MPO B cells in HC Tg mice seem to be nonfunctional.
CONCISE METHODS
Generation of V1C-J5 Light-Chain Tg Mice
A rearranged V1c-J5 light chain from an anti-MPO-specific hybridoma derived from SCG/Kj mice 12 was used to produce Tg mice. Genomic DNA from the 5F2 hybridoma was used to amplify the light chain by PCR using 5Ј TATAGAATTCCAGGTTCCACAGGTGAT-GTTTTGATGACCCAAACTC and 3Ј CAGTGAATTCTCTAGAA-GACCACGCTACCTG primers. The 642-bp PCR product was subcloned into a C/Neo expression vector containing the endogenous V21C promoter and leader sequences and C secretory exons 42 as similarly described for the V31/J4 light chain. 43 Vector DNA was linearized with SalI, injected into single-cell embryos, and transferred to pseudopregnant females (CB6 or CD1). Offspring carrying the 5F2 V1C-J5 transgene were identified by PCR analysis using the V1C forward (5Ј-GTTCCACAGGTGATGTTTTGAT-3Ј) and V4long reverse (5Ј-AGGAGCTGAACTTGACTTCAGC-3Ј) primers.
Six 5F2 transgene-positive founder mice were mated to B6C3F1 mice and backcrossed to C57BL/6 (Jackson Laboratory, Bar Harbor, ME). Mice from five of six founder lines were examined and had similar phenotypes; therefore, we focused our analysis on one of the lines. HC Tg mice resulted from interbreeding of LC Tg mice from this one founder line. Mice were maintained in a pathogen-free colony at the University of North Carolina Animal Facility. All animal protocols were approved by the Institutional Animal Care and Use Committee.
Taqman Quantitative PCR
Relative copy number of genomic V1C-J5 Tg mice was determined using real-time quantitative PCR quantification (Taqman) on ABI Prism 7900 HT sequence detector (Applied Biosystems [ABI], Foster City, CA). Quantitative PCR primers for V1C-J5 (accession no. AF113232) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; accession no. BC014085) were designed using Primer Express (V1.5; ABI). Forward and reverse primer pairs were GGCAGTGGATCAGG-GACAGAT (bp 216 to 237) and ACCGAACGTGAACGGAACA (bp 305 to 324) for V1C-J5 and GACCCCTTCATTGACCTCAACTAC and GCTCCTGGAAGATGGTGATGG for GAPDH. PCR reactions were performed using Taqman Universal PCR Master Mix (ABI) with SYBR Green (Molecular Probes, Eugene, OR) for fluorescence detection of amplified product. Primer linearity and proportionality were tested by PCR amplification of increasing dilutions of mouse genomic DNA. Relative quantification was performed by the ⌬⌬Ct method whereby the difference or fold change (FC) between samples was de-termined using the following equation: FC ϭ 2 (Ϫ⌬⌬Ct) . Relative transgene copy number was measured as a ratio to input genomic DNA as measured by GAPDH.
ELISA
Anti-MPO antibodies were detected in ELISA using native human MPO (Calbiochem, San Diego, CA), recombinant human MPO, or recombinant mouse MPO as described previously. 44, 45 Mouse and human recombinant MPO were expressed in HEK293 cells. 45 Calf thymus DNA (Sigma, St. Louis, MO) and native human PR3 (Elastin Products Company, Owensville, MO) served as control antigens. IgM production was measured by ELISA using goat antimouse Ig (SouthernBiotech, Birmingham, AL) as the capture antibody as described previously. 46 Plates were incubated with 100 l of hybridoma supernatant, splenocyte or B cell culture supernatants, or mouse sera diluted 1:10 to 1:250. Mouse IgM (SouthernBiotech), anti-mouse MPO mAb 8F4 (Hycult Biotechnology, Uden, Netherlands), and anti-human MPO mAb 2C7 (Abcam, Cambridge, MA) were used as positive controls as appropriate. Alkaline phosphatase-conjugated goat anti-mouse IgG and IgM (Pierce, Rockford, IL) or goat anti-mouse IgM (SouthernBiotech) were used as secondary antibodies. Reactivity was detected with an alkaline phosphatase substrate kit (Bio-Rad Laboratories, Hercules, CA). Samples giving an OD 405 value at least twice that of the negative control were considered positive.
Generation of B Cell Hybridomas
B cell hybridomas were generated from Tg mice as described previously. 12 Splenocytes from Tg mice were fused with P3X-Ag8.653 or NSObcl-2 myeloma cells. After fusion, tissue culture supernatants were screened for MPO binding by ELISA. Hybridomas expressing anti-MPO antibodies were rendered monoclonal by limiting dilution. Antibody isotype analysis was performed using a mouse mAb isotyping kit (Amersham Biosciences, Little Chalfont Buckinghamshire, England).
Analysis of Hybridoma Light-and Heavy-Chain V Region Genes
Total RNA was isolated from hybridomas producing anti-MPO antibodies using RNA STAT-60 (Tel-Test, Friendswood, TX); mRNA was isolated using the Poly(A)Tract Isolation System (Promega, Madison, WI). For confirmation that the transgene was transcribed, cDNA was generated with random hexamers and Superscript RT (Life Technologies, Gaithersburg, MD) after DNase (Life Technologies BRL) treatment of the poly (A) tail RNA template. Transgene-specific primers described previously were used to amplify the transgene. The diversity in light-chain and heavy-chain variable region gene usage was determined using the 5Ј Rapid Amplification of cDNA Ends system (5ЈRACE; Life Technologies) as described previously. 12 The GSP1 primers and nested GSP2 primers used for the kappa light chain and the Mu heavy chain were as follows: GSP1 5Ј-TAACTGCTCACTG-GATGGTGGGAAG-3Ј, GSP1 5Ј-CAGATTCTTATCAGACAG-3Ј, GSP2 5Ј-ATGGATACAGTTGGTGCAGCATCAG-3Ј, and GSP2 5Ј-GCTCTCGCAGGAGACGAG-3Ј.
PCR products were sequenced on an automated dye-chain termination DNA sequencer with nested constant region primers (GSP2) from the second round of PCR. Sequences were analyzed with Chromas (Technelysium, Helensvale, Australia) and Sci Ed Central (Scientific and Educational Software, Durham, NC). The Basic Local Alignment Search Tool (BLAST) was used to search the GenBank database for homology with murine V regions. IgBLAST was used to compare the sequences with the germline Ig database.
Flow Cytometry
Cells were isolated from the spleen, bone marrow, and peritoneum into HBSS containing 2% FBS as described previously. 46 Cells were stained with antibodies specific for IgM, CD21, CD23, CD43, CD5, B220, CD9, and CD11c that were conjugated to FITC, phycoerythrin, or allophycocyanin (BD Biosciences Pharmingen, San Diego, CA 
In Vitro Stimulation
Splenocytes were harvested as described previously for flow cytometry. Enriched populations of B cells were isolated by negative selection using a B cell enrichment kit (StemCell Technologies, Vancuouver, BC, Canada) and were Ͼ90% pure. Total splenocytes or B cells were cultured in duplicate for 3 to 5 d in DMEM-H, 10% FBS without stimulation or stimulated with native human MPO (10 to 20 g/ml; Calbiochem), LPS (10 g/ml; Invivogen), or anti-IgM F(abЈ) 2 (10 g/ml; JacksonImmunoResearch Laboratories, West Grove, PA). Supernatants were analyzed by ELISA. Proliferation of cells was measured using a CellTrace carboxyfluorescein diacetate, succinimidyl ester cell proliferation kit (Molecular Probes). Intracellular IgM was measured by blocking surface IgM with unlabeled goat anti-mouse IgM (SouthernBiotech) before permeabilization with Perm/Wash buffer (BD Biosciences Pharmingen) and subsequent staining with allophycocyanin-labeled antibody to IgM as described previously. 47 
Statistical Analysis
Baseline characteristics were summarized with means and SD. ANOVA tests were performed to evaluate differences in B cell variables among the three groups of mice (control, LC, and HC). Using a Duncan multiple range test to control for multiple comparisons, both the LC and HC were evaluated for statistical differences from the control group. To reduce the probability of finding differences between groups across different components of the same experiment because of multiple comparisons, a Bonferroni correction was used for adjusting the ␣ level to maintain an overall ␣ level of 0.05. Because 17 different components of the experiments were examined, an ad-justed ␣ level (0.05/17 ϭ 0.003) was used. Because of small sample sizes and skewed distribution, ranked variables were used in the analysis. All statistical programming and analyses were conducted using SAS 8.2 (SAS Institute, Cary, NC).
